Atlas Trials

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

Clinical trial NCT02787239 · COMPLETED

Trial details

NCT number
NCT02787239
Sponsor
Shanghai Henlius Biotech
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
B-cell Non Hodgkin's Lymphoma
Start date
2015-10-01
Primary completion
2018-05-01
Enrollment
407

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.